Towards better cellular replacement therapies in Parkinson disease
Preclinical animal studies using transplants of human fVM, on the other hand, showed more encouraging results (Clarke, Dunnett, Isacson, Sirinathsinghji, & Björklund, 1988; Dunnett, Isacson, Sirinathsinghji, Clarke, & Björklund, 1988). Consistent with the positive outcomes from animal models, human clinical trials using fVM produced significant motor improvement in the majority of the patients receiving the grafts (Wenning et al., 1997). Although overall clinical improvements are variable, both in strength and in duration, the fact that several individuals did enjoy long‐term benefits (more than 20 years) with robust graft survival and target tissue reinnervation endorses this tissue type as a viable option for cell transplantation (Kefalopoulou et al., 2014; Li et al., 2016), and spawned subsequent clinical trials including the ongoing TRANSEURO.
Despite these promising results, human fVM transplants suffer from several limitations that prevent the procedure from being widely used. The scarcity of suitable fetal tissue and ethical concerns are just two such barriers. The successful derivation of human embryonic stem cells (hESCs) in 1998 opened a new prospect of generating desired dopaminergic neurons for transplantation (Thomson et al., 1998). Subsequent years have witnessed a myriad of protocols being developed to guide the stem cells to tyrosine hydroxylase–expressing (TH+) dopaminergic neurons, culminating in the generation of “authentic” A9‐like DA neurons capable of tonic firing (Kirkeby et al., 2012; Kriks et al., 2011). In a series of preclinical animal models, these cells have been demonstrated to survive, integrate, innervate, and functionally rescue motor phenotypes of the animals with similar potency and efficacy compared with fetal tissue (Grealish et al., 2014). These experiments paved the way for clinical trials using these carefully differentiated cells, yet issues concerning ethics and immune rejection remain. More recently, clinical trials in humans have identified troubling dyskinesias in transplanted patients and a lack of efficacy in some patients despite postmortem evidence of reinnervation (Kordower et al., 2017).
The recent discovery of pluripotent stem cells induced from somatic cells (iPSCs) bypasses the above‐mentioned two issues and opens up the possibility of autologous transplants (Takahashi et al., 2007). The molecular profile and differentiation capacity of iPSCs have been demonstrated to be essentially equivalent to those of hESCs. Many labs have leveraged this approach to model PD, mostly focusing on characterizing the in vitro abnormal cellular phenotypes using dopaminergic neurons derived from PD iPSCs carrying the rare PD‐causing genes (such as LRRK2) (Bahmad et al., 2017; Nguyen et al., 2011). Fewer studies have examined idiopathic PDs, which account for the vast majority of PD. However, to use these cells in the clinical cell replacement setting for PD, critical parameters including graft survival, reinnervation, and motor function rescue must be rigorously evaluated in preclinical animal models.